TITLE:
AZD5438 in Patients With Advanced Solid Malignancies

CONDITION:
Neoplasms

INTERVENTION:
AZD5438

SUMMARY:

      Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to
      patients with advanced solid malignancies A review of the emerging clinical tolerability and
      exposure data from this study in conjunction with preclinical and the available clinical
      pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the
      development of AZD5438 as a potential anti-cancer agent would be discontinued.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Advanced solid malignancy

          -  Cancer refractory to standard treatments or for which no standard therapy exits

        Exclusion Criteria:

          -  Radiotherapy within 3 weeks of the start of treatment

          -  Investigational product within the last 3 weeks

          -  Systemic cytotoxic anti-cancer therapy within the last 3 weeks

          -  Any significant clinical disorder that makes it undesirable for the patient to
             participate
      
